These results suggest that while downregulation of both c-Myc and Mcl-1 are important contributors to voruciclib’s enhancement of venetoclax activity in AML cells, c-Myc may be more important than Mcl-1. This evidence concerns the gene MYC and acute myeloid leukemia.